Foghorn Therapeutics Inc. Stock Price, News & Analysis

Foghorn Therapeutics has entered into a strategic collaboration with Loxo Oncology at Lilly to develop novel oncology medicines utilizing Foghorn's Gene Traffic Control platform. The agreement includes a co-development and co-commercialization deal for Foghorn's selective BRM oncology program and another undisclosed program, alongside three additional discovery programs. Foghorn will receive $300 million upfront, along with an $80 million equity investment from Lilly at $20 per share. The partnership could yield up to $1.3 billion in potential milestones.

Loxo Oncology at Lilly and Foghorn Therapeutics announced a strategic collaboration aimed at developing novel oncology drugs using Foghorn's Gene Traffic Control platform. The agreement entails a $300 million upfront payment and an $80 million equity investment from Lilly. Foghorn will lead early research for their BRM-selective program, while Lilly will manage development and commercialization. They will share U.S. economics 50/50 and Foghorn stands to earn up to $1.3 billion in potential milestones. This collaboration addresses BRG1 mutations in various cancers, impacting a significant patient population.

Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company, will virtually participate in the 2021 Jefferies London Healthcare Conference. The event includes a presentation and investor 1x1 meetings, available on-demand from November 18, 2021, 8:00am GMT to November 19, 2021, 5:00pm GMT. Foghorn specializes in developing medicines that target the chromatin regulatory system and is advancing multiple oncology product candidates. For more details and the presentation access, visit www.foghorntx.com.

Foghorn Therapeutics (Nasdaq: FHTX) announced the dosing of the first patient in its phase 1 trial of FHD-609, a protein degrader targeting BRD9 for synovial sarcoma. The company is also advancing FHD-286, an inhibitor for metastatic uveal melanoma and relapsed AML. Recent highlights include participation in the Targeted Protein Degradation Summit and a financial update showing cash reserves of $120.8 million as of September 30, 2021. Foghorn plans to release initial data from both clinical programs in late 2021 and early 2022.

Foghorn Therapeutics (Nasdaq: FHTX) announced that its VP of Chemistry, David Millan, PhD, will present at the 4th Annual Targeted Protein Degradation Summit from October 26-29, 2021. Dr. Millan will discuss Foghorn's innovative protein degrader platform and its clinical asset, FHD-609, a heterobifunctional degrader of BRD9 aimed at treating synovial sarcoma. The company is advancing over eight protein degrader programs, with FHD-609 recently entering clinical trials, demonstrating potential in transforming treatment options for various cancers.

Foghorn Therapeutics (Nasdaq: FHTX) has announced its participation in two virtual investor conferences. The first is the Morgan Stanley Virtual Annual Global Healthcare Conference on September 9, 2021, featuring a fireside chat and one-on-one meetings. The second is the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, with a presentation and one-on-one meetings. Presentations will be available on-demand, and replays can be accessed for 90 days. Foghorn focuses on developing medicines that target the chromatin regulatory system in oncology.

Foghorn Therapeutics has announced the initiation of a first-in-human clinical trial for FHD-609, a selective protein degrader targeting BRD9, aimed at treating advanced synovial sarcoma. The trial marks a significant milestone for Foghorn's Gene Traffic Control platform, which focuses on addressing substantial unmet medical needs in oncology. FHD-609 seeks to exploit a synthetic lethal relationship with specific genetic mutations in synovial sarcoma. The company anticipates initial clinical data to be available in early 2022.

Foghorn Therapeutics has made significant advancements in its clinical programs, announcing the first patients dosed in Phase 1 trials of FHD-286 targeting metastatic uveal melanoma and relapsed acute myeloid leukemia. Additionally, they received IND clearance for FHD-609, a protein degrader for synovial sarcoma. The company's cash position as of June 30, 2021, stood at $141.3 million, down from $185.8 million at year-end 2020. Upcoming milestones include initial data for FHD-286 expected in Q4 2021 and for FHD-609 anticipated in H1 2022.

Foghorn Therapeutics (Nasdaq: FHTX) announced that Steven Bellon, Ph.D., Senior Vice President of Drug Discovery, will speak at the 2021 Wedbush PacGrow Healthcare Virtual Conference on August 11, 2021, at 10:20 a.m. ET. The panel titled 'Bullseye – Targeted Oncology Part 2' will discuss advancements in oncology. Additionally, Foghorn's management will conduct investor meetings during the event. A live webcast of the panel can be accessed in the Investors section of their website, www.foghorntx.com.